scispace - formally typeset
P

Paul Meraner

Researcher at University of Massachusetts Medical School

Publications -  10
Citations -  981

Paul Meraner is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Virus & Dengue virus. The author has an hindex of 9, co-authored 10 publications receiving 775 citations.

Papers
More filters
Journal ArticleDOI

Identification of Zika Virus and Dengue Virus Dependency Factors using Functional Genomics

TL;DR: It is found that both flaviviruses require the endoplasmic reticulum membrane complex for their early stages of infection, and insights are provided into the role of the EMC in flavivirus replication.
Journal ArticleDOI

Frizzled proteins are colonic epithelial receptors for C. difficile toxin B

TL;DR: FZDs are established as physiologically relevant receptors for TcdB in the colonic epithelium by carrying out CRISPR–Cas9-mediated genome-wide screens and identifying the members of the Wnt receptor frizzled family (FzDs) as TCDB receptors.
Journal ArticleDOI

The IFITMs Inhibit Zika Virus Replication

TL;DR: ITM1 and IFITM3 inhibit Zika virus infection early in the viral life cycle and can prevent Zika-virus-induced cell death, suggesting that strategies to boost the actions and/or levels of the IFITMs might be useful for inhibiting a broad range of emerging viruses.
Journal ArticleDOI

OR14I1 is a receptor for the human cytomegalovirus pentameric complex and defines viral epithelial cell tropism.

TL;DR: It is found that HCMV infection of epithelial cells is blocked by a synthetic OR14I1 peptide and inhibitors of adenylate cyclase and protein kinase A (PKA) signaling, which reveal previously unappreciated targets for the development of vaccines and antiviral therapies.
Journal ArticleDOI

Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes.

TL;DR: The results strongly support a model according to which IFITM3 accumulation at the sites of virus fusion is a prerequisite for its antiviral activity and that this protein traps viral fusion at a hemifusion stage by preventing the formation of fusion pores.